GlassScriptPhysician profile
Preeya Raghu
NPI 1558520015
$11,777.92
in general payments reported to CMS, 2019-2025
49 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,794 · 2020: $2,486 · 2021: $2,030 · 2022: $1,702 · 2023: $1,567 · 2024: $596 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,646.11 | 2019-2023 | Farxiga |
| Mannkind Corporation | $1,130.89 | 2019-2025 | Afrezza |
| Dexcom, INC. | $863.33 | 2019-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $857.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $712.01 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $619.33 | 2019-2025 | Evenity, Tepezza, Repatha |
| Sanofi-Aventis U.S. LLC | $617.92 | 2019-2024 | |
| Abbott Laboratories | $607.04 | 2020-2025 | Freestyle Libre 3 |
| Zealand Pharma US, INC. | $493.25 | 2020-2022 | |
| Abbvie INC. | $434.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.60 | 2019-2023 | Jardiance |
| Valeritas, INC. | $334.82 | 2019 | |
| Insulet Corporation | $332.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $293.33 | 2019-2023 | Steglatro |
| Intuity Medical INC | $234.39 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preeya Raghu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.